• Nurix Therapeutics Chief Legal Officer Christine Ring reported a net reduction in common stock holdings in an Aug. 3 filing.
• Sold 16,589 shares at a weighted average price of $23.05.
• Exercised employee stock options for 5,787 shares at $8.72.
• Ended with 9,110 shares of common stock beneficially owned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001817199-26-000028), on August 03, 2026, and is solely responsible for the information contained therein.